Ex VIvo DEtermiNed Cancer Therapy

EVIDENT's aim is to test if ex vivo drug screening can predict whether patients with solid cancers will respond, or not respond, to standard care treatments. Patients undergoing standard care surgery to excise their tumour, those undergoing a biopsy, or those having a fluid aspirate of a solid tumour with surplus tissue available after diagnostic use will be eligible for this study. The specimen will then be assessed with ex vivo drug screening utilising all standard therapies and therapies that are more novel and in early stages of development. The results of the ex vivo drug screen will be compared to the cancer's actual response to standard care treatments for those that undergo therapy to determine how effective the test is at predicting treatment response.

NCT Number	NCT05231655
Lead Sponsor	Sheffield Teaching Hospitals NHS Foundation Trust Collaborators: University of Sheffield
Conditions	Bladder Cancer, Kidney Cancer, Melanoma, Sarcoma, Glioblastoma, Head and Neck Cancer
Enrollment	600 participants
Start Date	2021-07-07
Primary Completion	2026-01 (estimated)
Study Completion	2027-01 (estimated)
Updated on ClinicalTrials.gov	2025-02-24